Bye Bye, Belviq?>
Drug Watch

Bye Bye, Belviq

by Health After 50  

It’s curtains for lorcaserin (Belviq, Belviq XR): The weight-loss drug has been recalled by the manufacturer at the request of the FDA because of fears that it might increase cancer risk.

The most frequent cancers reported in after-market clinical trials were pancreatic, colorectal, and lung. The recall, announced in February 2020, doesn’t warrant special cancer screenings among patients who were taking the drugs, says the FDA.

If you’re using lorcaserin, stop taking the drug and consult your doctor for alternative weight-loss medicines and strategies.

This content appears in the May 2020 issue of UC Berkeley Health After 50.

Also see Diet Drugs: A Losing Proposition and Behavioral Therapy for Obesity.